Study #2023-0043
A multicenter phase 1, open-label study of NB003 to assess safety, tolerability, pharmacokinetics and efficacy in patients with Advanced Malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
NB003 tablets
Description
This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor
Study phase:
Phase I
Physician name:
Neeta Somaiah
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-833-391-3015
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.